Avicanna | A Leader in Biopharmaceutical Advancement

Driving Biopharmaceutical Advancements of Naturally Derived and Evidence Based Products

Who We Are

Avicanna is a Canadian commercial-stage biopharmaceutical company

Leading in cannabinoid research, development, and evidence-based products for the global consumer medical and pharmaceutical segments.

Play Video

Avicanna 2022 Corporate Video

Corporate Overview

An International Biopharmaceutical Strategy

Four active business pillars – cosmetics, medical cannabis, pharmaceutical pipeline and active

Global opportunity – with completed transactions to 19 international markets

Established USDA organic certified vertical integration infrastructure – in Santa Marta, Colombia

Leading Scientific Platform and Intellectual Property Portfolio

Incubated JLABS @ Johnson & Johnson Innovation Centre, in the MaRS Discovery District

Canadian R&D and clinical infrastructure – in partnership with world-class institutions including UHN and U of T

30+ proprietary commercialized SKUs – from R&D to Canadian and international commercial channels

Pharmaceutical pipeline – addressing neurological, dermatological and pain indications

Intellectual Property and Brands Owned by Avicanna

Medical cannabis & wellness products – commercial

Cosmetics and Skincare – Commercial

Pharmaceutical pipeline – In development & registration stages

Active Pharmaceutical Ingredients (API) – Commercial

Commercial Pillars and Portfolio

Avicanna’s scientific platform has resulted in 30+ commercial and proprietary formulations and products

Including cosmetics, medical cannabis, pharmaceuticals in addition to its raw material business unit across international markets.

Commercial Stage
Medical Cannabis and Wellness Products

Commercial Stage
CBD Cosmetics and Skincare

In Development and Registration Stage
Pharmaceutical Pipeline

Commercial Stage
Cannabinoid API

Industry Leading Scientific Platform

Setting the Standard in the Cannabinoid Industry with Advanced and Evidence-Based Products Update to

Scientific Platform

R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products

R&D headquarters in Toronto, Canada with drug development pipeline including sustained release tablets, transdermal patches and nano-particle formulations.

30+

Proprietary Commercial Products

10+

Scientists

Canadian Government Research Grants Awarded Since 2020

Pending Patents

Health Canada Cannabis
Research Licenses to Avicanna
or Institutional Collaborators

World-class Institutional Collaborations

R&D and Clinical Partnerships Over the Past 4 Years

World-class Institutional Collaborations

20+ R&D, pre-clinical studies and research collaborations with Canada’s leading institutions and thought leaders since 2017

Majority of the research has been conducted in Canada through 4 Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators.